Imagine a cancer treatment that precisely targets malignant cells, leaving healthy ones untouched. Consider, also, a cancer treatment that corrects abnormal protein synthesis to produce healthy ...

I'm fighting a fatal disease that took the life of my brother. I work in biotech and know there are medical advances that might help. Government needs to let us try.

Solid Biosciences (NASDAQ:SLDB – Free Report) had its price objective boosted by Chardan Capital from $15.00 to $16.00 in a report published on Wednesday morning,Benzinga reports. The brokerage ...

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

On The Readout LOUD this week, STAT reporters discuss the FDA's staff cuts, how next-gen drugs may lead to too much weight ...

Solid Biosciences’ gene therapy uses a shortened version of the dystrophin protein, which is engineered to mimic the key functions of full-length dystrophin and allows it be delivered more effectively ...

Boston, USA-based biotech Solid Biosciences saw its shares rocket 36% to $5.48 yesterday, after the precision genetic ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Solid Biosciences Inc. (SLDB) shares surged more than 31% on Tuesday, their best session since January 2024, and extended ...

A Massachusetts man became the first person to try intranasal foralumab under an expanded access program for people with ...

The trial data, which was reported on February 18, 2025, also suggested potential cardiac benefits from the therapy. The company mentioned that SGT-003 has been well-tolerated with no serious adverse ...